Medical advisory board
David Plante, MD, PhD, Chair
Dr. Plante is Associate Professor of Psychiatry at the University of Wisconsin School of Medicine and Public Health. He is a Fellow of the American Academy of Sleep Medicine, member of the Sleep Research Society, and Program Director for the University of Wisconsin Sleep Medicine Fellowship. His current research uses high-density electroencephalography to study sleep and wakefulness in hypersomnia and affective disorders.
Dr. Plante is Associate Professor of Psychiatry at the University of Wisconsin School of Medicine and Public Health. He is a Fellow of the American Academy of Sleep Medicine, member of the Sleep Research Society, and Program Director for the University of Wisconsin Sleep Medicine Fellowship. His current research uses high-density electroencephalography to study sleep and wakefulness in hypersomnia and affective disorders.
Isabelle Arnulf, MD, PhD
Having authored more than 150 publications in peer-reviewed scientific journals, Professor Arnulf is not only one of the world’s leading experts on all forms of hypersomnia, including narcolepsy, idiopathic hypersomnia, and Kleine-Levin syndrome, but also Professor of Neurology at the Sorbonne Universités, Pierre and Marie Curie University, and head of the Sleep Disorder Service at the Pitié-Salpêtrière University Hospital in Paris, France. She trained with Dr. Michel Jouvet, who studied the function and mechanism of REM sleep soon after its discovery, and completed a postdoctoral fellowship with Dr. Emmanuel Mignot at Stanford University. Dr. Arnulf is the past-president of the French Sleep Society.
Having authored more than 150 publications in peer-reviewed scientific journals, Professor Arnulf is not only one of the world’s leading experts on all forms of hypersomnia, including narcolepsy, idiopathic hypersomnia, and Kleine-Levin syndrome, but also Professor of Neurology at the Sorbonne Universités, Pierre and Marie Curie University, and head of the Sleep Disorder Service at the Pitié-Salpêtrière University Hospital in Paris, France. She trained with Dr. Michel Jouvet, who studied the function and mechanism of REM sleep soon after its discovery, and completed a postdoctoral fellowship with Dr. Emmanuel Mignot at Stanford University. Dr. Arnulf is the past-president of the French Sleep Society.
Ana Krieger, MD
Dr. Krieger is Associate Professor of Clinical Medicine in the Departments of Medicine, Neurology, and Genetic Medicine at Weill Cornell Medical College. She is board certified in sleep medicine and the Medical Director of the Weill Cornell Center for Sleep Medicine. Dr. Krieger also holds board certification in internal medicine and pulmonary medicine and is a faculty member in the Division of Pulmonary and Critical Care Medicine, Department of Medicine, at Weill Cornell Medical College and an Associate Attending at the New York Presbyterian Hospital/Weill Cornell Medical Center and at Rockefeller University Hospital. Over the past 17 years, Dr. Krieger has been actively involved in clinical care and education, training sleep specialists, and conducting collaborative multidisciplinary research projects in sleep medicine. She serves as the Chair of the Sleep Deprivation Committee of the American Academy of Sleep Medicine and the President of the Northeast Sleep Society. Dr. Krieger is a Robert Wood Johnson Scholar, a Fellow of the Royal Society of Medicine, and a Fellow and Policy Advisor at the New York Academy of Medicine. She regularly contributes to media efforts aiming at achieving public awareness of sleep problems and a better understanding of their multifaceted consequences and treatment alternatives.
Dr. Krieger is Associate Professor of Clinical Medicine in the Departments of Medicine, Neurology, and Genetic Medicine at Weill Cornell Medical College. She is board certified in sleep medicine and the Medical Director of the Weill Cornell Center for Sleep Medicine. Dr. Krieger also holds board certification in internal medicine and pulmonary medicine and is a faculty member in the Division of Pulmonary and Critical Care Medicine, Department of Medicine, at Weill Cornell Medical College and an Associate Attending at the New York Presbyterian Hospital/Weill Cornell Medical Center and at Rockefeller University Hospital.
Over the past 17 years, Dr. Krieger has been actively involved in clinical care and education, training sleep specialists, and conducting collaborative multidisciplinary research projects in sleep medicine. She serves as the Chair of the Sleep Deprivation Committee of the American Academy of Sleep Medicine and the President of the Northeast Sleep Society. Dr. Krieger is a Robert Wood Johnson Scholar, a Fellow of the Royal Society of Medicine, and a Fellow and Policy Advisor at the New York Academy of Medicine. She regularly contributes to media efforts aiming at achieving public awareness of sleep problems and a better understanding of their multifaceted consequences and treatment alternatives.
Gert Jan Lammers, MD, PhD
Dr. Lammers trained as a neurologist and clinical neurophysiologist at Leiden University Medical Center, then earned a PhD at Leiden University with a thesis titled "Narcolepsy." He is currently a professor of neurology at Leiden University, and the primary focus of his research is on narcolepsy and related disorders of hypersomnolence. Dr. Lammers is one of the founding members of the European Narcolepsy Network, which is an organization of clinicians and researchers across all of Europe with a focus on central disorders of hypersomnolence in general, and he served as President of the organization from 2007-2014. In 2013, he obtained the qualification of Somnologist from the European Sleep Research Society, and he was appointed as fellow of the European Neurological Association in 2021. After founding a new sleep/wake center in 2013, he became the Medical Director of all three sleep/wake centers of SEIN, which is the Dutch center of excellence for epilepsy and sleep disorders. Dr. Lammers is the current chair of the Dutch Society for Sleep Medicine. He has published extensively (more than 180 PubMed cited papers), including on diagnostic criteria and pharmacological treatment of idiopathic hypersomnia.
Dr. Lammers trained as a neurologist and clinical neurophysiologist at Leiden University Medical Center, then earned a PhD at Leiden University with a thesis titled "Narcolepsy." He is currently a professor of neurology at Leiden University, and the primary focus of his research is on narcolepsy and related disorders of hypersomnolence. Dr. Lammers is one of the founding members of the European Narcolepsy Network, which is an organization of clinicians and researchers across all of Europe with a focus on central disorders of hypersomnolence in general, and he served as President of the organization from 2007-2014. In 2013, he obtained the qualification of Somnologist from the European Sleep Research Society, and he was appointed as fellow of the European Neurological Association in 2021. After founding a new sleep/wake center in 2013, he became the Medical Director of all three sleep/wake centers of SEIN, which is the Dutch center of excellence for epilepsy and sleep disorders. Dr. Lammers is the current chair of the Dutch Society for Sleep Medicine. He has published extensively (more than 180 PubMed cited papers), including on diagnostic criteria and pharmacological treatment of idiopathic hypersomnia.
Kiran Maski, MD, MPH
Kiran Maski, MD, MPH, is an assistant professor at Harvard Medical School and a child neurologist and sleep medicine specialist at Boston Children’s Hospital. She received her medical degree from the University of Wisconsin and completed her general pediatric residency at Tufts-New England Medical Center. She received her pediatric neurology residency and pediatric sleep fellowship training at Boston Children’s Hospital (BCH). She now runs the Neurology Sleep Clinic at BCH and is the assistant program director for the Child Neurology Residency. Dr. Maski’s clinical work and research is focused on pediatric narcolepsy. Dr. Maski has created a hypersomnia clinic at BCH where she sees children and young adults with central nervous system hypersomnia conditions from all over the world. She is an advocate for pediatric narcolepsy, promoting awareness of this condition among health care providers and schools. She was honored with the “Outstanding Physician” award by Wake Up Narcolepsy, a patient advocacy group, for this work in 2015. Dr. Maski currently serves as the Chairperson of the American Academy of Sleep Medicine Task Force for the Treatment of Central Nervous System Hypersomnias. Her clinical research in narcolepsy is focused on neurophysiological biomarkers that help diagnose and treat narcolepsy patients. She has received grant support from the American Academy of Neurology, American Sleep Medicine Foundation, Wake Up Narcolepsy, BCH Research Council Fund, and Jazz Pharmceuticals, Inc.
Kiran Maski, MD, MPH, is an assistant professor at Harvard Medical School and a child neurologist and sleep medicine specialist at Boston Children’s Hospital. She received her medical degree from the University of Wisconsin and completed her general pediatric residency at Tufts-New England Medical Center. She received her pediatric neurology residency and pediatric sleep fellowship training at Boston Children’s Hospital (BCH). She now runs the Neurology Sleep Clinic at BCH and is the assistant program director for the Child Neurology Residency. Dr. Maski’s clinical work and research is focused on pediatric narcolepsy. Dr. Maski has created a hypersomnia clinic at BCH where she sees children and young adults with central nervous system hypersomnia conditions from all over the world. She is an advocate for pediatric narcolepsy, promoting awareness of this condition among health care providers and schools. She was honored with the “Outstanding Physician” award by Wake Up Narcolepsy, a patient advocacy group, for this work in 2015. Dr. Maski currently serves as the Chairperson of the American Academy of Sleep Medicine Task Force for the Treatment of Central Nervous System Hypersomnias. Her clinical research in narcolepsy is focused on neurophysiological biomarkers that help diagnose and treat narcolepsy patients. She has received grant support from the American Academy of Neurology, American Sleep Medicine Foundation, Wake Up Narcolepsy, BCH Research Council Fund, and Jazz Pharmceuticals, Inc.
Anne Marie Morse, DO, FAASM
Dr. Anne Marie Morse is a board-certified and fellowship-trained pediatric neurologist. She currently serves as the Director of Child Neurology and Pediatric Sleep Medicine at Geisinger, Janet Weis Children's Hospital. Her clinical interests include sleep-wake disorders in neurologic disease, narcolepsy, hypersomnia disorders, and neuroimmunology. Her research interests include sleep-wake disorders in neurologic disease, hypersomnia disorders, and sleep-wake disorder phenotyping. Dr. Morse earned her degree in osteopathic medicine from Rowan University. She completed her residency and her child neurology fellowship at the State University of New York, Downstate Medical Center. She completed another fellowship in sleep medicine at the Albert Einstein College of Medicine of Yeshiva University, Montefiore Medical Center. Dr. Morse is certified by the American Board of Psychiatry and Neurology in neurology with a special qualification in child neurology.
Dr. Anne Marie Morse is a board-certified and fellowship-trained pediatric neurologist. She currently serves as the Director of Child Neurology and Pediatric Sleep Medicine at Geisinger, Janet Weis Children's Hospital. Her clinical interests include sleep-wake disorders in neurologic disease, narcolepsy, hypersomnia disorders, and neuroimmunology. Her research interests include sleep-wake disorders in neurologic disease, hypersomnia disorders, and sleep-wake disorder phenotyping. Dr. Morse earned her degree in osteopathic medicine from Rowan University. She completed her residency and her child neurology fellowship at the State University of New York, Downstate Medical Center. She completed another fellowship in sleep medicine at the Albert Einstein College of Medicine of Yeshiva University, Montefiore Medical Center. Dr. Morse is certified by the American Board of Psychiatry and Neurology in neurology with a special qualification in child neurology.
Jason Ong, PhD, DBSM
Dr. Ong is the Director of Behavioral Sleep Medicine at Nox Health and an Adjunct Associate Professor of Neurology at Northwestern University Feinberg School of Medicine. He received his PhD in clinical psychology from Virginia Commonwealth University and completed a fellowship in Behavioral Sleep Medicine at Stanford University Medical Center. His research interest involves demonstrating the effectiveness and value of behavioral treatments for sleep disorders, including cognitive-behavioral therapy and mindfulness meditation. Related to hypersomnias, Dr. Ong is involved in studies examining the psychosocial impact of hypersomnias and behavioral interventions to improve quality of life in people with hypersomnias.
Dr. Ong is the Director of Behavioral Sleep Medicine at Nox Health and an Adjunct Associate Professor of Neurology at Northwestern University Feinberg School of Medicine. He received his PhD in clinical psychology from Virginia Commonwealth University and completed a fellowship in Behavioral Sleep Medicine at Stanford University Medical Center. His research interest involves demonstrating the effectiveness and value of behavioral treatments for sleep disorders, including cognitive-behavioral therapy and mindfulness meditation. Related to hypersomnias, Dr. Ong is involved in studies examining the psychosocial impact of hypersomnias and behavioral interventions to improve quality of life in people with hypersomnias.
Chad Ruoff, MD
Dr. Ruoff is a Senior Associate Consultant in sleep medicine at the Mayo Clinic Arizona. He is board certified in sleep medicine, obesity medicine, and internal medicine. Dr. Ruoff’s career in sleep medicine began as a sleep technologist in 1998, while completing his undergraduate education at Georgetown University. He received his internal medicine training at Baylor College of Medicine and then completed a sleep medicine fellowship at Stanford University in 2011, after which he joined the Stanford sleep faculty. Later, he spent a few years practicing sleep and obesity medicine at Kaiser in Woodland Hills, CA, before moving on to Mayo in 2020. He has developed a strong interest in the clinical evaluation and treatment of CNS hypersomnias, and is active in research and on AASM task forces.
Dr. Ruoff is a Senior Associate Consultant in sleep medicine at the Mayo Clinic Arizona. He is board certified in sleep medicine, obesity medicine, and internal medicine. Dr. Ruoff’s career in sleep medicine began as a sleep technologist in 1998, while completing his undergraduate education at Georgetown University. He received his internal medicine training at Baylor College of Medicine and then completed a sleep medicine fellowship at Stanford University in 2011, after which he joined the Stanford sleep faculty. Later, he spent a few years practicing sleep and obesity medicine at Kaiser in Woodland Hills, CA, before moving on to Mayo in 2020. He has developed a strong interest in the clinical evaluation and treatment of CNS hypersomnias, and is active in research and on AASM task forces.
Mandeep Singh, MBBS, MD, MSc, FRCPC
Dr. Singh completed his Anesthesiology training at the University of Toronto, and later completed his Sleep Medicine fellowship training at the University of Toronto. He has the distinction of being the first Canadian physician to be dual-specialized in Sleep Medicine and Anesthesiology. He also completed a Masters in Clinical Epidemiology and Health Sciences Research from the University of Toronto. His current research interests include evaluating the perioperative (before and after surgery) outcomes in patients with sleep disorders, including disorders of daytime hypersomnolence. Dr. Singh is one of the authors of an article published last year about the anesthesia concerns for patients with idiopathic hypersomnia (IH) who are considering surgery.
Dr. Singh completed his Anesthesiology training at the University of Toronto, and later completed his Sleep Medicine fellowship training at the University of Toronto. He has the distinction of being the first Canadian physician to be dual-specialized in Sleep Medicine and Anesthesiology. He also completed a Masters in Clinical Epidemiology and Health Sciences Research from the University of Toronto.
His current research interests include evaluating the perioperative (before and after surgery) outcomes in patients with sleep disorders, including disorders of daytime hypersomnolence. Dr. Singh is one of the authors of an article published last year about the anesthesia concerns for patients with idiopathic hypersomnia (IH) who are considering surgery.
Lynn Marie Trotti, MD, MSc
Dr. Trotti is Associate Professor of Neurology at Emory University in Atlanta, GA. She graduated from Baylor College of Medicine and completed her neurology residency, sleep fellowship, and Masters of Science in Clinical Research at Emory. Her main area of clinical and research interest is the central disorders of hypersomnolence. Dr. Trotti is currently funded by the National Institutes of Health and the American Academy of Sleep Medicine Foundation as the principal investigator of two clinical trials investigating treatments for hypersomnolence. She is the recipient of the Hypersomnia Foundation's 2020 Impact Award. In bestowing this award, the Foundation noted her outstanding and ongoing contributions to IH research, her exceptional care of her patients, and her multiple advocacy and education efforts as Chair of the Foundation's Medical Advisory Board from its inception in 2014 through 2020.
Dr. Trotti is Associate Professor of Neurology at Emory University in Atlanta, GA. She graduated from Baylor College of Medicine and completed her neurology residency, sleep fellowship, and Masters of Science in Clinical Research at Emory. Her main area of clinical and research interest is the central disorders of hypersomnolence. Dr. Trotti is currently funded by the National Institutes of Health and the American Academy of Sleep Medicine Foundation as the principal investigator of two clinical trials investigating treatments for hypersomnolence. She is the recipient of the Hypersomnia Foundation's 2020 Impact Award. In bestowing this award, the Foundation noted her outstanding and ongoing contributions to IH research, her exceptional care of her patients, and her multiple advocacy and education efforts as Chair of the Foundation's Medical Advisory Board from its inception in 2014 through 2020.
Scientific advisory board
Thanh Dang-Vu, MD, PhD, Chair
Dr. Dang-Vu is Associate Professor at Concordia University in Montreal, where he currently holds the University Research Chair in Sleep, Neuroimaging and Cognitive Health. He is also an attending neurologist and the Associate Director for Clinical Research at the Institut Universitaire de Gériatrie de Montréal, a Clinical Assistant Professor of Neuroscience at University of Montreal, and an Adjunct Professor of Neurology and Neurosurgery at McGill University. Dr. Dang-Vu received his MD and PhD from the Université de Liège in Belgium, and completed post-doctoral fellowships in the department of Neurology at the Massachusetts General Hospital and Harvard Medical School, as well as at the Center for Advanced Research in Sleep Medicine at the Université de Montreal. His research is focused, in part, on the pathophysiology of sleep disorders using multimodal neuroimaging and EEG, including his team’s 2017 brain imaging study, which found that participants with IH showed regional cerebral blood flow differences compared to participants without IH.
Dr. Dang-Vu is Associate Professor at Concordia University in Montreal, where he currently holds the University Research Chair in Sleep, Neuroimaging and Cognitive Health. He is also an attending neurologist and the Associate Director for Clinical Research at the Institut Universitaire de Gériatrie de Montréal, a Clinical Assistant Professor of Neuroscience at University of Montreal, and an Adjunct Professor of Neurology and Neurosurgery at McGill University. Dr. Dang-Vu received his MD and PhD from the Université de Liège in Belgium, and completed post-doctoral fellowships in the department of Neurology at the Massachusetts General Hospital and Harvard Medical School, as well as at the Center for Advanced Research in Sleep Medicine at the Université de Montreal. His research is focused, in part, on the pathophysiology of sleep disorders using multimodal neuroimaging and EEG, including his team’s 2017 brain imaging study, which found that participants with IH showed regional cerebral blood flow differences compared to participants without IH.
Dale M. Edgar, PhD
Dale M. Edgar, PhD, is an accomplished scientist, educator, drug hunter, and entrepreneur in the field of sleep medicine. His distinguished career spans nearly 30 years and the breadth of academia to industry. During his 15 years at Stanford University’s School of Medicine, Dr. Edgar achieved international recognition as a leader in discovering how the brain and its chemistry modulate sleep/wake and bodily rhythms. In 2000, Dr. Edgar co-founded Hypnion, Inc.—a spin-out of the unique technologies that he developed at Stanford. At Hypnion, he led preclinical and clinical research teams tasked with developing novel medicines to treat insomnia and disorders of excessive sleepiness. Upon Hypnion’s acquisition by Eli Lilly & Company in 2007, Dr. Edgar transitioned to Chief Scientific Leader of Discovery Sleep Research at Lilly – a cross-functional preclinical and clinical R&D function, focusing on innovative medicines for sleep disorders and sleep-related comorbidities in psychiatry, pain, neurodegenerative disease, and metabolic disease. His expertise, passion, and contributions led to numerous other global leadership roles with Lilly, which importantly kept him intimately involved in translating discoveries to patient care, as well as ensuring that the communities of stake holders necessary to move these discoveries forward was sustainable. Having recently retired from Lilly, Dr. Edgar is now co-founder and senior vice president of research at Novion Pharmaceuticals, a start-up neuroscience biotechnology company focused on the discovery and development of novel treatments for sleep disorders.
Dale M. Edgar, PhD, is an accomplished scientist, educator, drug hunter, and entrepreneur in the field of sleep medicine. His distinguished career spans nearly 30 years and the breadth of academia to industry. During his 15 years at Stanford University’s School of Medicine, Dr. Edgar achieved international recognition as a leader in discovering how the brain and its chemistry modulate sleep/wake and bodily rhythms. In 2000, Dr. Edgar co-founded Hypnion, Inc.—a spin-out of the unique technologies that he developed at Stanford. At Hypnion, he led preclinical and clinical research teams tasked with developing novel medicines to treat insomnia and disorders of excessive sleepiness. Upon Hypnion’s acquisition by Eli Lilly & Company in 2007, Dr. Edgar transitioned to Chief Scientific Leader of Discovery Sleep Research at Lilly – a cross-functional preclinical and clinical R&D function, focusing on innovative medicines for sleep disorders and sleep-related comorbidities in psychiatry, pain, neurodegenerative disease, and metabolic disease. His expertise, passion, and contributions led to numerous other global leadership roles with Lilly, which importantly kept him intimately involved in translating discoveries to patient care, as well as ensuring that the communities of stake holders necessary to move these discoveries forward was sustainable. Having recently retired from Lilly, Dr. Edgar is now co-founder and senior vice president of research at Novion Pharmaceuticals, a start-up neuroscience biotechnology company focused on the discovery and development of novel treatments for sleep disorders.
Professor Nicholas Franks, FRSB, FRCA, FMedSci, FRS
As Professor of Biophysics & Anaesthetics at London’s Imperial College, Prof. Nicholas Franks has sought to understand how general anesthetic agents work at the molecular, cellular, and, most recently, neuronal network levels. Almost 40 years ago, he asked the question, “Where do general anaesthetics act?” in the journal Nature and has been pursuing the answer through funded studies in his laboratory since that time. Along the way, he has expanded his research to better understand the relationships among anesthesia, consciousness, and sleep and has also asked, and answered, the question, “Do sedatives engage natural sleep pathways?” Among the many discoveries that he has made throughout his long and storied career, Prof. Franks recently identified the exact binding location of propofol to the GABA-A receptor. In 2007, Prof. Franks was elected Fellow of the Royal College of Anaesthetists and, in 2011, Fellow of the Royal Society. He has been awarded the Ebert Prize of the American Pharmaceutical Association, the Gold Medal of the Royal College of Anaesthetists, and the Excellence in Research Award from the American Society of Anesthesiologists.
As Professor of Biophysics & Anaesthetics at London’s Imperial College, Prof. Nicholas Franks has sought to understand how general anesthetic agents work at the molecular, cellular, and, most recently, neuronal network levels. Almost 40 years ago, he asked the question, “Where do general anaesthetics act?” in the journal Nature and has been pursuing the answer through funded studies in his laboratory since that time. Along the way, he has expanded his research to better understand the relationships among anesthesia, consciousness, and sleep and has also asked, and answered, the question, “Do sedatives engage natural sleep pathways?” Among the many discoveries that he has made throughout his long and storied career, Prof. Franks recently identified the exact binding location of propofol to the GABA-A receptor.
In 2007, Prof. Franks was elected Fellow of the Royal College of Anaesthetists and, in 2011, Fellow of the Royal Society. He has been awarded the Ebert Prize of the American Pharmaceutical Association, the Gold Medal of the Royal College of Anaesthetists, and the Excellence in Research Award from the American Society of Anesthesiologists.
Jeff Gulcher, MD, PhD
Jeff Gulcher, MD, PhD, is Chief Scientific Officer for WuXi NextCODE. Previously he was Chief Scientific Officer and co-founder of deCODE Genetics. Dr. Gulcher was on staff in the Department of Neurology at Beth Israel Hospital and Harvard Medical School from 1993 to 1998. He received his PhD and MD from the University of Chicago in 1990 and completed his neurology residency at Brigham and Women’s Hospital and Beth Israel Hospital of Harvard Medical School in 1996. He received a Bachelor’s Degree in Chemistry/Physics from Michigan State University in 1981. He has co-authored 198 peer-reviewed publications on the genetics of common/complex diseases.
Jeff Gulcher, MD, PhD, is Chief Scientific Officer for WuXi NextCODE. Previously he was Chief Scientific Officer and co-founder of deCODE Genetics. Dr. Gulcher was on staff in the Department of Neurology at Beth Israel Hospital and Harvard Medical School from 1993 to 1998. He received his PhD and MD from the University of Chicago in 1990 and completed his neurology residency at Brigham and Women’s Hospital and Beth Israel Hospital of Harvard Medical School in 1996. He received a Bachelor’s Degree in Chemistry/Physics from Michigan State University in 1981. He has co-authored 198 peer-reviewed publications on the genetics of common/complex diseases.
James M. Krueger, PhD
Dr. Krueger is Regents Professor of Neuroscience in the Elson S. Floyd College of Medicine at Washington State University. Early in his career as a postdoctoral fellow, Dr. Krueger worked with Dr. John Pappenheimer to isolate, purify, and characterize Factor S and subsequently published their seminal work in The Proceedings of the National Academy in 1978. Today he is recognized as a worldwide expert on sleep in his own right. Among Dr. Krueger’s numerous awards are election to the Washington State Academy of Sciences, recipient of the Doctorem Medicinae Honoris Causa from the University of Szeged, the Distinguished Scientist Award from the Sleep Research Society, and the Senator Jacob Javits Award in the Neurosciences from the National Institutes of Health. Dr. Krueger’s research has been continuously funded by the National Institutes of Health for over 28 years; it is focused on the biochemical regulation of sleep, molecular mechanisms responsible for the effects of infectious diseases and inflammation on sleep, sleep function, and brain organization of the initiation of sleep. Dr. Krueger’s 350 peer-reviewed publications cover the gamut from sleep function to sleep and cytokines, and to physiological markers of localized sleep. His latest research documents his theoretical predictions that sleep originates in small neural networks, discoveries that open the door to a deeper appreciation of the genetic, molecular, and electrical aspects of sleep disorders.
Dr. Krueger is Regents Professor of Neuroscience in the Elson S. Floyd College of Medicine at Washington State University. Early in his career as a postdoctoral fellow, Dr. Krueger worked with Dr. John Pappenheimer to isolate, purify, and characterize Factor S and subsequently published their seminal work in The Proceedings of the National Academy in 1978. Today he is recognized as a worldwide expert on sleep in his own right.
Among Dr. Krueger’s numerous awards are election to the Washington State Academy of Sciences, recipient of the Doctorem Medicinae Honoris Causa from the University of Szeged, the Distinguished Scientist Award from the Sleep Research Society, and the Senator Jacob Javits Award in the Neurosciences from the National Institutes of Health.
Dr. Krueger’s research has been continuously funded by the National Institutes of Health for over 28 years; it is focused on the biochemical regulation of sleep, molecular mechanisms responsible for the effects of infectious diseases and inflammation on sleep, sleep function, and brain organization of the initiation of sleep. Dr. Krueger’s 350 peer-reviewed publications cover the gamut from sleep function to sleep and cytokines, and to physiological markers of localized sleep. His latest research documents his theoretical predictions that sleep originates in small neural networks, discoveries that open the door to a deeper appreciation of the genetic, molecular, and electrical aspects of sleep disorders.
David Rye, MD, PhD
Dr. Rye is Professor of Neurology at Emory University, board certified in Neurology and Sleep Medicine. He has received the American Academy of Neurology’s Sleep Science Award and the Sleep Research Society’s Outstanding Scientific Achievement Award for the discovery of the genetic contributions of restless legs syndrome. In June of 2019, Dr. Rye received the Hypersomnia Foundation’s first Impact Award, for his pivotal work in the area in researching and treating idiopathic hypersomnia, and his support of HF’s efforts to provide education on IH and related disorders to patients, health providers and, through PBS’s “Your Fantastic Mind” series, the general public. He has also received Narcolepsy Network’s Researcher of the Year Award, which recognizes the Emory team’s more recent contribution to our understanding of the origins and treatments for hypersomnia. He and the Emory team are making new discoveries into the origins and treatments of hypersomnia that are transforming the way medicine is practiced. Dr. Rye is a former (founding) Chair of HF's scientific advisory board.
Dr. Rye is Professor of Neurology at Emory University, board certified in Neurology and Sleep Medicine. He has received the American Academy of Neurology’s Sleep Science Award and the Sleep Research Society’s Outstanding Scientific Achievement Award for the discovery of the genetic contributions of restless legs syndrome. In June of 2019, Dr. Rye received the Hypersomnia Foundation’s first Impact Award, for his pivotal work in the area in researching and treating idiopathic hypersomnia, and his support of HF’s efforts to provide education on IH and related disorders to patients, health providers and, through PBS’s “Your Fantastic Mind” series, the general public. He has also received Narcolepsy Network’s Researcher of the Year Award, which recognizes the Emory team’s more recent contribution to our understanding of the origins and treatments for hypersomnia. He and the Emory team are making new discoveries into the origins and treatments of hypersomnia that are transforming the way medicine is practiced. Dr. Rye is a former (founding) Chair of HF's scientific advisory board.